Completed NA INTERVENTIONAL NCT00602849

Bioequivalency Study of Sertraline Under Fasting Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fasting Conditions

Sponsor: Roxane Laboratories

Conditions Depression

Interventions Sertraline

Updated 6 times since 2017 Last updated: Jan 19, 2018 Started: Jun 30, 2003 Primary completion: Jul 31, 2003 Completion: Jul 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00602849, this NA trial focuses on Depression and remains completed. Sponsored by Roxane Laboratories, it has been updated 6 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2018 — Jun 2018 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Completed NA

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxane Laboratories

Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sainte-Fly, Canada